A Phase 1 interventional study of ABBV-295 and Placebo in Obesity, sponsored by AbbVie. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 80 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.
Drug: ABBV-295 · Drug: Placebo
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.
Drug: ABBV-295 · Drug: Placebo
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.
Drug: ABBV-295 · Drug: Placebo
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks or 20 weeks.
Drug: ABBV-295 · Drug: Placebo
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.
Drug: ABBV-295 · Drug: Placebo
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks or 20 weeks.
Drug: ABBV-295 · Drug: Placebo
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 20 weeks.
Drug: ABBV-295 · Drug: Placebo
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 20 weeks.
Drug: ABBV-295 · Drug: Placebo
Subcutaneous Injections
Subcutaneous Injections
Number of Participants with Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Time frame: Up to approximately 194 days
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
Number of participants with abnormal change from baseline in vital sign measurements like heart rate, systolic and diastolic blood pressure will be assessed.
Time frame: Up to approximately 194 days
Number of Participants with Change from Baseline in Electrocardiogram (ECG)
12-lead resting ECG will be recorded.
Time frame: Up to approximately 194 days
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
Number of participants with abnormal change in clinical laboratory test results like biochemistry, hematology will be assessed.
Time frame: Up to approximately 194 days
Maximum Observed Plasma Concentration (Cmax) of ABBV-295
Cmax of ABBV-295
Time frame: Up to approximately 194 days
Time to Cmax (Tmax) of ABBV-295
Tmax of ABBV-295
Time frame: Up to approximately 194 days
Trough plasma concentration (Ctrough) of ABBV-295
Ctrough of ABBV-295
Time frame: Up to approximately 194 days
Apparent terminal phase elimination rate constant (BETA) of ABBV-295
BETA of ABBV-295
Time frame: Up to approximately 194 days
Terminal phase elimination half-life (t1/2) of ABBV-295
t1/2 of ABBV-295
Time frame: Up to approximately 194 days
Area under the plasma concentration-time curve (AUC) of ABBV-295
AUC of ABBV-295
Time frame: Up to approximately 194 days
Area under the plasma concentration-time curve over the dosing interval (AUCtau) of ABBV-295
AUCtau of ABBV-295
Time frame: Up to approximately 194 days
Dose Normalized Cmax of ABBV-295
Dose normalized Cmax of ABBV-295 will be assessed.
Time frame: Up to approximately 194 days
Dose Normalized AUC of ABBV-295
Dose normalized AUC of ABBV-295 will be assessed.
Time frame: Up to approximately 194 days
Incidence of Anti-Drug Antibodies (ADAs)
Incidence of ADAs will be assessed.
Time frame: Up to approximately 194 days
Percent Change in Body Weight From Baseline
Percent change in body weight (kg) will be assessed.
Time frame: Up to approximately 194 days
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Apr 2027, 17 months after the start.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 17 months is above that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Mar 2027 → Apr 2027 and completion Mar 2027 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABBV-295